ProQR Therapeutics (PRQR) CEO boosts stake with 200,000-share buy

Rhea-AI Filing Summary

ProQR Therapeutics N.V. reports that Chief Executive Officer Daniel Anton de Boer purchased 200,000 Ordinary Shares on 2026-07-31 at $1.7698 per share in a transaction described as a purchase in open market or private transaction, increasing his direct holdings to 500,000 shares. The Rule 10b5-1 trading-plan checkbox was not marked for this transaction.

Insider Trade Summary

Net Buyer: 200,000 shares

Net Buy 1 txn

Insider de Boer Daniel Anton

Role Chief Executive Officer

Bought 200,000 shs ($354K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	200,000	$1.7698	$354K

Holdings After Transaction: Ordinary Shares — 500,000 shares (Direct)

Key Figures

Shares purchased: 200,000 shares Purchase price: $1.7698 per share Holdings after transaction: 500,000 shares +1 more

4 metrics

Shares purchased 200,000 shares Ordinary Shares bought on 2026-07-31

Purchase price $1.7698 per share Price for Ordinary Shares purchased on 2026-07-31

Holdings after transaction 500,000 shares Direct Ordinary Share holdings following reported purchase

Net shares bought 200,000 shares Net buy shares in transaction summary

Key Terms

Ordinary Shares, non-derivative, Purchase in open market or private transaction

3 terms

Ordinary Shares financial

""security_title": "Ordinary Shares" in the transaction record"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

non-derivative financial

""transaction_type": "non-derivative" for this insider trade"

Purchase in open market or private transaction financial

"transaction_code_description: "Purchase in open market or private transaction""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/03/2026 - 04:01 PM Accepted by SEC EDGAR 08/03/2026 - 04:01 PM Learn about SEC filing dates

FAQ

What insider transaction did ProQR (PRQR) disclose in this Form 4?

ProQR disclosed that CEO Daniel Anton de Boer purchased 200,000 Ordinary Shares on 2026-07-31 at $1.7698 per share. The trade is reported as a purchase in open market or private transaction and increased his direct holdings to 500,000 shares.

Who is the insider involved in the latest ProQR (PRQR) share purchase?

The insider is Daniel Anton de Boer, ProQR’s Chief Executive Officer and director. He bought 200,000 Ordinary Shares, bringing his directly held stake to 500,000 shares, according to the reported non-derivative transaction dated 2026-07-31.

At what price did the ProQR (PRQR) CEO buy the ordinary shares?

The CEO’s purchase was reported at a price of $1.7698 per share for 200,000 Ordinary Shares. This per-share price applies to the non-derivative transaction described as a purchase in open market or private transaction on 2026-07-31.

How many ProQR (PRQR) shares does the CEO hold after this transaction?

After the reported purchase, CEO Daniel Anton de Boer directly holds 500,000 Ordinary Shares. This total includes the 200,000 shares acquired on 2026-07-31 and represents his direct ownership position following the non-derivative transaction.

Was the ProQR (PRQR) CEO’s share purchase under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked, indicating the reported 200,000-share purchase was not affirmatively identified as made under a Rule 10b5-1 trading plan. The transaction is simply described as an open market or private purchase.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

de Boer Daniel Anton

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/31/2026		P		200,000	A	$1.7698	500,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)